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Objectives This study was undertaken to determine the safety and feasibility of extraction of the Sprint Fidelis (Medtronic,
Minneapolis, Minnesota) lead.
Background The reported failure rate of the Sprint Fidelis defibrillator lead has increased to a range greater than initially ap-
preciated with emerging evidence of an accelerating rate of fracture. At present, consensus guidelines continue
to recommend against prophylactic extraction of the lead, citing major complication rates between 1.4% and
7.3%. However, data regarding the safety and feasibility of extraction of small-diameter, backfilled implantable
cardioverter-defibrillator leads such as the Sprint Fidelis are limited.
Methods We performed a retrospective cohort study of consecutive patients undergoing extraction of Sprint Fidelis (mod-
els 6930, 6931, 6948, 6949) leads at 5 high-volume centers. Patient characteristics, indications for extraction,
and use of countertraction sheath (CTS) assistance are reported. The risk of major and minor complications was
determined. A multivariable logistic regression model was developed to predict factors associated with the use
of CTS assistance.
Results Between May 2005 and August 2009, 349 Sprint Fidelis leads were extracted from 348 patients. All leads were re-
moved completely. The average duration of the implanted lead was 27.5 months (range 0.03 to 58.8 months). Ap-
proximately one-half of the extracted leads were fractured (49.4%), and 26.5% were extracted prophylactically. The
other major indication for extraction was infection (22.8%). Extraction was achieved with simple traction in 49.4%
leads; CTS assistance was required in 174 cases (50.6%). In multivariable models, length of time since implantation
was directly related to the need for CTS assistance (odds ratio per month since implantation: 1.035; 95% confidence
interval: 1.010 to 1.061; p  0.006). There were no major procedural complications or deaths.
Conclusions Extraction of the Sprint Fidelis lead can be performed safely by experienced operators at high-volume centers
with a complication rate lower than that reported for older generation leads. However, leads with longer implant
durations are associated with the use of CTS assistance. Recommendations regarding prophylactic Sprint Fidelis
lead extraction may warrant reconsideration. (J Am Coll Cardiol 2010;56:646–50) © 2010 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.03.058e
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ortality (6,7), clinicians remain uncertain as to the best
anagement of patients with active and failed Sprint Fidelis
efibrillator leads. Available management options include
bservation (for functioning leads), adding a new implant-
ble cardioverter-defibrillator (ICD) or pace sense lead to
he system while abandoning the Fidelis lead, and extracting
he Fidelis lead and reimplanting a new ICD lead.
See page 651
At present, consensus guidelines recommend against pro-
hylactic extraction of the lead, citing major complication rates
etween 1.4% and 7.3% (8). These data cited by Medtronic
egarding the risks of extraction are incomplete and not current
8). More recent registries at high-volume centers have re-
orted high success rates with exceedingly low complication
ates (0.4% to 0.9%) (9,10). Moreover, data regarding the
afety and feasibility of extraction of a small-diameter, back-
lled ICD leads such as the Sprint Fidelis, with a relatively
hort implant duration, are limited. This study examined the
xperience at 5 extraction referral centers with regard to
xtraction of the Sprint Fidelis lead and assessment of the
orbidity and mortality of this procedure when performed by
xperienced, high-volume operators.
ethods
e identified a cohort of consecutive patients undergoing
xtraction of Medtronic Sprint Fidelis (models 6930, 6931,
948, 6949) leads at 5 high-volume centers and retrospectively
nalyzed patient characteristics, procedural outcomes, and
omplications. The lead extraction technique used was the
ecision of the operator. All operators are highly skilled and
ell versed in all extraction modalities with a large volume of
xperience (100 lead extractions/year). Patient characteristics
nd the indications, outcomes, and need for countertraction
heath (CTS) assistance were examined. Logistic regression
nalysis was performed to identify predictors of the use of CTS
nd to correct for possible confounders.
Outcomes were based on the most recent Heart Rhythm
ociety lead management consensus (11) and defined as
ollows: 1) complete procedural success if all targeted leads
nd lead material were removed from the vascular space;
) clinical success if all targeted leads and lead material were
emoved but with retention of a small portion of the lead
hat does not negatively affect outcome goals; and 3) failure
f neither complete procedural nor clinical success could be
chieved. Major complications were defined as death; car-
iac or vascular avulsion or tear requiring thoracotomy,
ericardiocentesis, chest tube, or surgical repair; pulmonary
mbolism requiring surgical intervention; respiratory arrest
r anesthesia complication leading to prolongation of hos-
italization; stroke; and pacing system-related infection of a
reviously noninfected site; minor complications were de-
ned as pericardial effusion not requiring pericardiocentesis
Vr surgical intervention; hemo-
horax not requiring a chest tube;
ematoma at the surgical site
equiring reoperation for drain-
ge; arm swelling or thrombosis
f implant veins resulting in
edical intervention; vascular re-
air near the implant site or ve-
ous entry site; hemodynamically
ignificant air embolism; migrated lead fragment without
equelae; blood transfusion related to blood loss during
urgery; pneumothorax requiring a chest tube; and pulmo-
ary embolism not requiring surgical intervention. Patients
ere followed in-hospital, and 30-day procedure-related
utcomes are reported.
Means, medians, and proportions for baseline clinical
ariables were calculated for the entire cohort. Continuous
ariables were expressed as mean  SD or median and
nterquartile range (IQR). Chi-square tests were used to
ompare categorical variables. Student t tests were used to
ompare normally distributed continuous variables, and
ilcoxon rank sum tests were used for continuous variables
hat were not normally distributed. Logistic regression
nalysis was used to identify clinical variables associated
ith CTS assistance. Variables in the multivariable logistic
egression model included age at extraction, sex, presence of
nfection, left ventricular ejection fraction, number of leads
mplanted, implant duration, and clinical site. Age at
xtraction and implant duration were modeled as continu-
us variables after the linearity assumption was tested.
issing value indicators were created for variables with
issing covariate data (left ventricular ejection fraction and
umber of leads). All tests of significance were 2 sided, and
p value of 0.05 was considered significant. Statistical
ata analysis was performed using SAS version 9.1.3 (SAS
nstitute, Cary, North Carolina).
aseline Patient CharacteristicsTable 1 Baseline Patient Characteristics
Age (yrs) 60 16
Male sex 73.3
Etiology of cardiomyopathy
Ischemic 47.6
Nonischemic 25.6
Other 26.2
Ejection fraction (%) 34 15
New York Heart Association functional class (n)
I 28
II 30
III 36
IV 6
ICD indication (primary prevention) 74.6
Number of implanted leads 2.2 0.9
Previous cardiac surgery 34.6
Pacemaker dependence 22.9
Abbreviations
and Acronyms
CTS  countertraction
sheath assistance
ICD  implantable
cardioverter-defibrillator
IQR  interquartile rangealues are mean  SD or % unless otherwise indicated.
ICD  implantable cardioverter-defibrillator.
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etween May 2005 and August 2009, a total of 349 Sprint
idelis leads were removed from 348 patients. Baseline
haracteristics are presented in Table 1. The mean patient
ge at the time of the procedure was 59.9  16 years
median 63 years, IQR 50 to 72 years), and 74% were men.
he majority (48%) of patients had underlying ischemic
ardiomyopathy. Twenty-six percent had nonischemic car-
iomyopathy, and the remainder had other cardiac condi-
ions such as hypertrophic cardiomyopathy, cardiac sarcoid,
nd arrhythmogenic right ventricular cardiomyopathy. The
ean ejection fraction was 34.1  15.1% (median 31%,
QR 21% to 45%). The indication for device implantation
as primary prevention in 75% of patients. Pacemaker
ependence was present in 22% of patients, and 34% had
revious cardiac surgery.
The predominant Sprint Fidelis lead model extracted was
he dual-coil, active-fixation lead (model 6949, 80.4%),
ollowed by the single-coil, active-fixation lead (model
931, 10.0%), the dual-coil, passive-fixation lead (model
948, 9.2%), and the single-coil, passive-fixation lead
model 6930, 0.4%). The average number of intravascular
eads was 2.2  0.9 (range 1 to 5). The mean implant
uration was 27.5  14.2 months (median 27.6 months,
QR 17.4 to 37.4 months); the oldest lead was in place for
8.8 months. Indications for lead extraction are listed in
able 2. The most common indication was lead fracture
49.4%), followed by prophylactic reasons (26.5%) and
nfection (22.8%).
Complete procedural success was achieved in all proce-
ures. Extraction was achieved with simple traction in 170
f 344 leads (49.4%). Powered CTS assistance was used
ith the Excimer Laser System (Spectranetics, Colorado
prings, Colorado) in 142 cases (41.9%) and the Evolution
evice (Cook Medical, Bloomington, Indiana) in 3 cases
0.9%). Mechanical CTS assistance with a telescoping
heath was used in 27 cases (7.9%).
In univariate analysis, CTS assistance was associated with a
onger mean implant duration compared with leads extracted
ith simple traction (25.4  14.7 months vs. 29.6  13.7
onths; p  0.006) and younger age (odds ratio: 0.972; p 
.0004). In multivariable analysis (Table 3), CTS assistance
as significantly associated with longer lead implant duration,
oninfected versus infected leads, and younger age. For each
dditional month’s duration of lead implant, the odds of
equiring CTS assistance increased significantly by 3.5%
ndications for ExtractionTable 2 Indications for Extraction
Fracture 49.4%
Prophylactic 26.5%
Infection 22.8%
Other
Painful insertion site 0.9%A95% confidence interval: 1.01% to 1.06%). The presence of
nfection had the most dramatic impact on the need for
TS assistance. Patients with either local or systemic
nfection had markedly reduced odds of requiring CTS
ssistance (odds ratio: 0.15; 95% confidence interval: 0.041
o 0.572).
There were no major in-hospital complications associated
ith lead extraction. The mean estimated blood loss per
rocedure was 103  65 ml (median 50 ml, IQR 20 to 100
l). There were 2 minor procedural complications (0.57%).
o procedure-related deaths occurred (Table 4). There
ere 3 in-hospital deaths due to overwhelming sepsis in
atients who presented with sepsis/endocarditis.
iscussion
n October 15, 2007, Medtronic voluntarily suspended
istribution of the Sprint Fidelis lead due to growing
oncerns regarding an abnormally high fracture rate with
65 lead failures and 5 potential resultant deaths (12). Initial
erformance reports from Medtronic did not identify a
tatistically significant difference in lead survival compared
ith other lead models such as the Sprint Quattro, although
he difference was projected to reach statistical significance
f the failure rate remained constant. Recommendations
egarding management included routine monitoring with
djustment of impedance alarm thresholds. Medtronic and
ts Independent Physician Quality Panel deemed the current
ailure rate of 2.3% at 30 months inadequate to justify
rophylactic lead replacement, citing major complication
ates of extraction between 1.4% and 7.3% (8,13–15).
Since this initial report, several groups have reported obser-
ations of higher failure rates (2,3,16). Krahn et al. (16)
escribed a 3.91% failure rate at 32 months in a cohort of 6,215
eads implanted in multiple centers across Canada. Subse-
uently, Hauser and Hayes (3) reported a significantly higher
dds Ratio Estimates ofredictors of the Need for CTS AssistanceTable 3 Odds Rati Estimate ofPredictors of the Need for CTS Assistance
Point Estimate 95% CI
Age (yrs) 0.970 0.949–0.991
Male sex 0.989 0.505–1.938
Lead implant duration (months) 1.035 1.010–1.061
Infection* 0.153 0.041–0.572
Number of leads (2 vs. 2) 2.335 0.878–6.212
Ejection fraction 1.073 0.383–3.010
I  confidence interval; CTS  countertraction sheath.
Infectious indication for extraction versus noninfectious indication.
rocedural ComplicationsTable 4 Procedural Complications
Traction CTS Assistance Total
Deaths (n) 0 0 0
Major complications (n) 0 0 0
Minor complications: lead dislodgment (n) 0 2 2R-wave undersensing 0.6%
bbreviation as in Table 3.
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-year survival rate of 87.9% in a series of 848 leads implanted
t 2 centers. Despite these reports and evidence of an expo-
entially increasing rate of failure (2), Medtronic has continued
o recommend against extraction, stating that the “risk of
rophylactic intervention appears to be greater than the risk of
erious injury resulting from lead fracture” (7).
We provide the first data regarding the safety and feasibility
f transvenous extraction of the Sprint Fidelis lead. In our
xperience with 349 Sprint Fidelis leads, we observed complete
rocedural success in all cases with no major complications or
rocedure-related deaths regardless of the method of extrac-
ion. The minor in-hospital complication rate was 0.57% and
ell within reported complication rates for device implantation
17). The minor complications seen in this cohort were not
ssociated with the lead extraction itself; rather, they are risks
ssociated with any cardiac rhythm device implant. As is the
ase with extraction of other leads (14,18,19), we found that
ead implant duration, younger patient age, and the absence of
nfection were associated with a significant increase in the need
or CTS assistance, thereby increasing the complexity of the
xtraction procedure.
The management of patients with an implanted Sprint
idelis ICD lead is challenging. Pocket or systemic infec-
ion is a class 1 indication for complete device and lead
emoval. Therefore, in the setting of a device-related infec-
ion, management of a patient with a Sprint Fidelis lead is
straightforward decision. The management of noninfected
atients with a fractured or functional Sprint Fidelis ICD
ead is more difficult. The options include adding a new
ace-sense lead, adding a new ICD lead, and extracting and
eplacing the fractured lead. The risks of each of these
ptions need to be carefully considered on a case-by-case
asis as stated in the 2009 Heart Rhythm Society Expert
onsensus document on transvenous lead extraction (11).
he first option of adding a pace-sense lead is suboptimal
iven the 10% failure rate of the high-voltage portion of the
ead (10), particularly among patients with fractured leads
hat have already demonstrated failure of 1 component. The
rst and second options require consideration of the risks
ssociated with abandoned leads, data for which are both
ontradictory and limited. The reported complication rates
f abandoned leads vary widely from insignificant to 20%,
ith the majority of available data from abandoned pace-
aker and not defibrillator leads (20–25). Most authorities
ould agree that the incontrovertible risks of defibrillator
ead abandonment are related to the potential need for
uture extraction, with 1 report of the risk of extraction
oubling every 3 years (15) and the higher number of leads
resent at the time of extraction increasing the rate of
otential complications (26). In the present study, we
emonstrate that the risks associated with the third option,
ead extraction, when performed in experienced centers, are
ow enough to consider extraction of fractured Sprint Fidelis
eads as a primary approach, especially among younger iatients. In our cohort of 348 patients and 349 Sprint
idelis leads, there were no deaths or major complications.
In the present study, we also demonstrated that for each
onth since the initial implantation of the Sprint Fidelis
ead, the odds of requiring CTS assistance increase signif-
cantly by 3.5%. Given the exponential failure rate for the
print Fidelis ICD lead (1–3), these data raise the concern
hat a strategy of surveillance followed by removal only
hen the lead fails may not be the best strategy. Although
eaving the lead intact with implementation of the Lead
ntegrity Alert software patch (Medtronic, Minneapolis,
innesota) is “expected to provide three days advance notice
rior to inappropriate therapy to 76% of the patients with lead
ractures” (7), its utility remains to be tested (4–6). ICD lead
racture is associated with significant morbidity and even
ortality. The fracture can result in nondelivery of pacing or
efibrillator therapy, which can be particularly dangerous in
atients who are pacemaker dependent, have a history of
ppropriate therapy, or received their device for a secondary
revention indication (2,6). Inappropriate shocks have signif-
cant negative psychological effects (27), and, although rare,
nappropriate therapy can induce a life-threatening arrhythmia,
hich may not be treated due to lead failure (6). In addition,
ecent studies suggest that inappropriate shocks themselves can
ave a negative impact on mortality (28–30). Therefore, in
atients in whom lead failure could be particularly danger-
us and who may be at higher risk of failure (young age,
ormal ejection fraction, noncephalic access, right-sided
mplants, subpectoral position) (2,31), consideration of
rophylactic extraction, especially at the time of generator
hange, when the risk of pocket infection is already present,
ay also be warranted.
Decisions regarding extraction of the Sprint Fidelis lead
ust be made on a case-by-case basis considering multiple
atient- and physician-related variables. An invasive ap-
roach, with the potential for significant morbidity and
ortality, may not be warranted in patients with a poor
rognosis or in whom the risks of intervention clearly
utweigh the benefits. In addition, lead extractions should
ot be performed by those inexperienced in the procedure,
y those without the necessary tools available to attain
omplete success, or in a setting not prepared and commit-
ed to the complete and safe performance of the procedure.
tudy limitations. The major limitation of this study is
hat it represents a retrospective analysis of the experience of
high-volume centers. As such, these data and outcomes
ay not be replicated in the general community. We are,
herefore, not advocating the widespread extraction of
print Fidelis leads. Deaths have been reported in patients
ndergoing Sprint Fidelis extraction (7). In addition, this
tudy was not designed to compare different approaches to
he management of patients with a Sprint Fidelis lead.
herefore, no definitive conclusions regarding optimal
anagement can be drawn from this study. Finally,
ollow-up was limited to the index hospitalization and the
mmediate post-procedure period. Given the referral nature
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omplications could be unrecognized.
onclusions
n this multicenter experience, transvenous extraction of the
print Fidelis lead was performed with a 100% success rate
nd a low rate of minor complications, with no associated
ajor complications or mortality. Independent predictors of
he need for CTS assistance included longer lead implant
uration, younger patient age, and the absence of a device-
elated infection. We are not advocating that all Sprint
idelis leads be extracted. The present study demonstrates
hat, in selected patients and in experienced hands, the
urrent recommendations regarding Sprint Fidelis lead ex-
raction warrant reconsideration.
ddendum
ince manuscript submission, the authors have performed
n additional 208 Fidelis lead extractions for a total of 557
eads removed with 100% complete procedural success.
here were no major complications and no procedural
eaths. The authors believe that this additional data em-
hasizes that transvenous extraction of the Sprint Fidelis
ead can be a safe procedure in experienced hands.
eprint requests and correspondence: Dr. Melanie Maytin,
righam and Women’s Hospital, 75 Francis Street, Boston,
assachusetts 02115. E-mail: mmaytin@partners.org.
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